AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis

Published on January 17, 2022

FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 and above. This is the third indication for Rinvoq in...

Continue reading on website
Other news

Vail Resorts (MTN) Reports Ski Season Metrics, Skier Visits Down

January 17, 2022
Vail Resorts (MTN) season-to-date (through Jan 2, 2022) total skier visits fell 1.7% compared with the prior year season-to-date period (Jan 3, 2021).

Can Travelers (TRV) Retain Its Surprise Streak in Q4 Earnings?

January 17, 2022
Travelers' (TRV) fourth-quarter results are likely to reflect strength across its segments.